Physician profile
Danny D Le
NPI 1144507112
$6,123.69
in general payments reported to CMS, 2019-2025
31 companies · $896 in 2025
The $896 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $472 · 2021: $465 · 2022: $751 · 2023: $1,080 · 2024: $1,094 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,984.55 | 2019-2025 | Esprit, Pressurewire, Xience Sierra |
| Boston Scientific Corporation | $661.87 | 2019-2025 | Bodyguardian, Avvigo Guidance System, Opticross 6 |
| Inari Medical, INC. | $594.60 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $506.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $464.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $417.00 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $235.46 | 2019-2023 | Eliquis, Camzyos, Opdualag |
| Medtronic, INC. | $231.52 | 2022-2024 | Onyx Frontier |
| Pfizer INC. | $165.80 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $131.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $129.40 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.79 | 2019-2022 | |
| Philips North America LLC | $66.21 | 2020-2025 | (Ck7) Extended Holter, Extended Holter |
| Amgen INC. | $48.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.42 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avinger INC. | $47.27 | 2022 | |
| Novo Nordisk INC | $40.33 | 2022-2025 | Wegovy |
| Biotronik INC. | $37.76 | 2019-2021 | |
| Edwards Lifesciences Corporation | $28.95 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals International, Plc | $22.00 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.97 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.44 | 2024 | Lifevest |
| Surmodics, INC. | $19.05 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.00 | 2025 | Onpattro |
| Organogenesis INC. | $17.83 | 2020 | |
| Terumo Medical Corporation | $15.31 | 2022 | |
| Cvrx, INC. | $14.75 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $14.50 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.45 | 2021 | |
| Tactile Systems Technology INC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.